[go: up one dir, main page]

BR0315302A - Benzoxazinonas substituìdas e seus usos - Google Patents

Benzoxazinonas substituìdas e seus usos

Info

Publication number
BR0315302A
BR0315302A BR0315302-9A BR0315302A BR0315302A BR 0315302 A BR0315302 A BR 0315302A BR 0315302 A BR0315302 A BR 0315302A BR 0315302 A BR0315302 A BR 0315302A
Authority
BR
Brazil
Prior art keywords
substituted benzoxazinones
formula
benzoxazinones
substituted
methods
Prior art date
Application number
BR0315302-9A
Other languages
English (en)
Inventor
Hans Maag
Meng Sui
Shu-Hai Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0315302A publication Critical patent/BR0315302A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"BENZOXAZINONAS SUBSTITUìDAS E SEUS USOS". A presente invenção provê composto da Fórmula (1) e seus sais ou pró-drogas farmaceuticamente aceitáveis, onde Y, Z, R^ 1, R^ 2^, R^ 3^, R^ 4^, R^ 5^, R^ 6^, R^ 7^, R^ 8^, R^ 9^, m, n, p e q são conforme aqui definido. A invenção também provê métodos para preparação, composições compreendendo e métodos para uso de compostos da Fórmula (I).
BR0315302-9A 2002-11-08 2003-11-04 Benzoxazinonas substituìdas e seus usos BR0315302A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42494602P 2002-11-08 2002-11-08
PCT/EP2003/012278 WO2004041792A1 (en) 2002-11-08 2003-11-04 Substituted benzoxazinones and uses thereof

Publications (1)

Publication Number Publication Date
BR0315302A true BR0315302A (pt) 2005-08-23

Family

ID=32312902

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315302-9A BR0315302A (pt) 2002-11-08 2003-11-04 Benzoxazinonas substituìdas e seus usos

Country Status (28)

Country Link
US (1) US7141562B2 (pt)
EP (1) EP1562918B1 (pt)
JP (1) JP4401297B2 (pt)
KR (1) KR100683361B1 (pt)
CN (1) CN100390157C (pt)
AR (1) AR042002A1 (pt)
AT (1) ATE384054T1 (pt)
AU (1) AU2003293653B2 (pt)
BR (1) BR0315302A (pt)
CA (1) CA2505334A1 (pt)
DE (1) DE60318733T2 (pt)
DK (1) DK1562918T3 (pt)
ES (1) ES2298609T3 (pt)
GT (1) GT200300241A (pt)
HR (1) HRP20050390A2 (pt)
IL (1) IL168343A (pt)
MX (1) MXPA05004758A (pt)
MY (1) MY136824A (pt)
NO (1) NO20052074L (pt)
NZ (1) NZ539508A (pt)
PA (1) PA8587501A1 (pt)
PE (1) PE20040828A1 (pt)
PL (1) PL377770A1 (pt)
PT (1) PT1562918E (pt)
RU (1) RU2328490C2 (pt)
TW (1) TWI285639B (pt)
WO (1) WO2004041792A1 (pt)
ZA (1) ZA200503248B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5080716B2 (ja) * 2001-07-20 2012-11-21 サイコジェニックス・インコーポレーテッド 注意欠陥・多動性障害の治療
AU2003219103B2 (en) 2002-03-27 2008-10-23 Axovant Sciences Gmbh Quinoline derivatives and their use as 5-HT6 ligands
TW200523253A (en) 2003-07-22 2005-07-16 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
RU2354651C2 (ru) 2003-12-09 2009-05-10 Ф.Хоффманн-Ля Рош Аг Производные бензоксазина и их применение
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
MX2007003545A (es) * 2004-09-30 2007-05-18 Hoffmann La Roche Composiciones y metodos para tratar trastornos cognitivos.
MX2008000411A (es) 2005-07-13 2008-03-10 Hoffmann La Roche Derivados de bencimidazol como 5-ht6, 5-ht2a.
EP1954689A4 (en) * 2005-09-15 2009-09-02 Korea Res Inst Chem Tech N-SUBSTITUTED 1H-CHINOLIN-2,4-DIONE, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
ATE509636T1 (de) * 2006-06-23 2011-06-15 Esteve Labor Dr Kombination aus einem cholinesterase-hemmer und einer verbindung mit 5-ht6-rezeptor-affinität
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
ITMI20131782A1 (it) * 2013-10-25 2015-04-26 Dipharma Francis Srl Procedimento per la preparazione di un agonista della trombopoietina
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
RU2624978C2 (ru) * 2015-07-27 2017-07-11 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ лечения умеренного когнитивного снижения
MD3649124T2 (ro) * 2017-08-07 2021-07-31 Suven Life Sciences Ltd Compuși de fluoropiperidină ca antagoniști puri ai receptorului 5-HT6
CN111559990B (zh) * 2020-05-29 2021-03-09 四川大学华西医院 一种小分子噁噻嗪类衍生物及其应用
CN112047898A (zh) * 2020-10-14 2020-12-08 兰州大学 一种苯并[c][1,2]噁嗪骨架类新化合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3586794T2 (de) 1984-12-21 1993-05-27 Duphar Int Res Arzneimittel mit psychotroper wirkung.
AU605304B2 (en) * 1987-06-22 1991-01-10 Nihon Tokushu Nayaku Seizo K.K. Benzo-fused cyclic compounds
FR2667068B1 (fr) * 1990-09-26 1994-09-09 Adir Nouvelles amines alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5955470A (en) * 1991-06-11 1999-09-21 Merrell Pharmaceuticals, Inc. Derivatives of amide analogs of certain methano bridged quinolizines
CA2250347C (en) 1996-03-29 2006-02-21 Duphar International Research B.V. Piperazine and piperidine compounds with high affinity for dopamine-d2 and serotonin-5ht1a receptors
ATE253058T1 (de) 1997-09-02 2003-11-15 Duphar Int Res Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten
CN1155596C (zh) * 1999-08-23 2004-06-30 索尔瓦药物有限公司 新的苯基哌嗪
AU2001236606A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. 3,4-dihydro-2h-benzo(1,4)oxazine inhibitors of factor xa
US20020019394A1 (en) 2000-03-24 2002-02-14 Wenhao Li Bicyclic sulfonyl amino inhibitors of factor Xa
DE10031391A1 (de) 2000-07-03 2002-02-07 Knoll Ag Bicyclische Verbindungen und ihre Verwendung zur Prophylaxe und Therapie der zerebralen Ischämie
CZ20031163A3 (cs) * 2000-10-26 2004-04-14 Smithkline Beecham P. L. C. Deriváty benzoxazinonu, způsob jejich přípravy, jejich použití a farmaceutický prostředek, který je obsahuje
ATE417838T1 (de) * 2001-08-10 2009-01-15 Hoffmann La Roche Arylsulfonyl-derivate mit 5-ht 6-rezeptor- affinität
KR100636475B1 (ko) * 2002-05-13 2006-10-18 에프. 호프만-라 로슈 아게 5-ｈｔ6 조절제로서 벤족사진 유도체 및 이의 용도

Also Published As

Publication number Publication date
CN100390157C (zh) 2008-05-28
PA8587501A1 (es) 2004-05-26
KR20050072479A (ko) 2005-07-11
EP1562918A1 (en) 2005-08-17
ZA200503248B (en) 2006-02-22
KR100683361B1 (ko) 2007-02-15
ATE384054T1 (de) 2008-02-15
PT1562918E (pt) 2008-03-12
JP4401297B2 (ja) 2010-01-20
GT200300241A (es) 2004-06-03
NO20052074L (no) 2005-06-01
PL377770A1 (pl) 2006-02-20
DK1562918T3 (da) 2008-05-05
MXPA05004758A (es) 2005-08-02
AU2003293653A1 (en) 2004-06-07
IL168343A (en) 2010-05-31
CN1723205A (zh) 2006-01-18
EP1562918B1 (en) 2008-01-16
WO2004041792A1 (en) 2004-05-21
RU2328490C2 (ru) 2008-07-10
RU2005117965A (ru) 2006-01-27
US20040092512A1 (en) 2004-05-13
JP2006514615A (ja) 2006-05-11
AU2003293653B2 (en) 2009-05-14
US7141562B2 (en) 2006-11-28
DE60318733D1 (de) 2008-03-06
PE20040828A1 (es) 2004-11-25
CA2505334A1 (en) 2004-05-21
MY136824A (en) 2008-11-28
ES2298609T3 (es) 2008-05-16
NZ539508A (en) 2007-05-31
TWI285639B (en) 2007-08-21
AR042002A1 (es) 2005-06-08
DE60318733T2 (de) 2009-01-15
HRP20050390A2 (en) 2006-12-31
TW200418846A (en) 2004-10-01

Similar Documents

Publication Publication Date Title
BR0315302A (pt) Benzoxazinonas substituìdas e seus usos
DK1625126T3 (da) Imidazo- og thiazolopyridiner som JAK3-kinaseinhibitorer
UA83091C2 (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
SE9904652D0 (sv) Novel Compounds
BR0205890A (pt) Pirazolopirimidinas como agentes terapêuticos
BRPI0410714B8 (pt) derivados de quinazolina macrocíclicos, seu processo de preparação, composição farmacêutica que os compreende e uso
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
BRPI0416853A (pt) pirazolila e imidazolila pirimidinas
NO20024614L (no) N-heterosykliske derivater som NOS-hemmere
BRPI0410669A (pt) inibidores de caspase e usos dos mesmo
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
BRPI0507818A (pt) composto e métodos de inibição
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
DK1606242T3 (da) Azidfri fremgangsmåde til fremstilling af 1,2-diaminoforbindelser
ATE300541T1 (de) Pyrazolopyridinderivate
BRPI0409105A (pt) análogos de quinobenzoxazina substituìdos
SE0302139D0 (sv) Novel compounds
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
UY27424A1 (es) Agentes antidiabéticos
BR0313917A (pt) Composições antimicrobianas
MY139612A (en) Benzoxazine derivatives as 5-th6 modulators and uses thereof
BRPI0416873A (pt) derivados de benzoxazina e usos dos mesmos
NO20054135L (no) Kipolinon/benzoksazin derivater og anvendelser derav
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]